CYTOライブシグナル | Getagraph.comで利益を最大化

売る 114977 min ago

@ $1.986

発行日: 10 2月 2024 @ 05:25

リターン: -17.93%

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

Stats
本日の出来高	33 694.00
平均出来高	1.21M
時価総額	3.65M
EPS	$0 ( 2024-04-10 )
次の収益日	( $0 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.0180 (1.10%)

Insider Trading

Date	Person	Action	Amount	type
2008-05-08	Carter Stephen	Sell	10 000	Common Stock
2008-05-08	Lokay Kevin G	Sell	185 439	Common Stock
2008-05-08	Lokay Kevin G	Sell	100 000	Options to Purchase Common Stock
2008-05-08	Mollica Joseph A	Sell	10 000	Common Stock
2007-11-13	Lokay Kevin G	Buy	500 000	Options to purchase Common Stock par value $0.01

INSIDER POWER
0.00
Last 33 transactions
Buy: 1 218 228 \| Sell: 315 439

ボリューム相関

長: -0.13 (neutral)

短: -0.10 (neutral)

Signal:(43.818) Neutral

Altamira Therapeutics 相関

10 最も正の相関
PIII	0.951
PROC	0.95
DISH	0.948
LGMK	0.945
AHCO	0.944
LGHL	0.942
EVLO	0.942
TTEC	0.941
MDRX	0.941
UPC	0.94

10 最も負の相関
VKTX	-0.965
JMAC	-0.965
IQ	-0.96
DKDCA	-0.96
CMPO	-0.957
HHGC	-0.956
IVCP	-0.956
AIB	-0.951
OVLY	-0.951
ACLS	-0.951

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Altamira Therapeutics 相関 - 通貨/商品

-0.06
( neutral )

0.00
( neutral )

0.06
( neutral )

0.42
( neutral )

0.27
( neutral )

Altamira Therapeutics 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-14.80

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-14.80

FY	2022
収益:	$305 616
総利益:	$-1.14M (-372.44 %)
EPS:	$-29.13

FY	2021
収益:	$63 882.00
総利益:	$-2.18M (-3 407.33 %)
EPS:	$-3.24

Financial Reports:

No articles found.

Altamira Therapeutics

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.